CN104820099A - 一种同时检测血浆中TPSⅡ、SSA、hs-CRP、PCT和抵抗素含量的试剂盒及其应用 - Google Patents
一种同时检测血浆中TPSⅡ、SSA、hs-CRP、PCT和抵抗素含量的试剂盒及其应用 Download PDFInfo
- Publication number
- CN104820099A CN104820099A CN201510176406.XA CN201510176406A CN104820099A CN 104820099 A CN104820099 A CN 104820099A CN 201510176406 A CN201510176406 A CN 201510176406A CN 104820099 A CN104820099 A CN 104820099A
- Authority
- CN
- China
- Prior art keywords
- crp
- kit
- ssa
- pct
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title claims abstract description 51
- 210000002381 plasma Anatomy 0.000 title claims abstract description 9
- 102000007156 Resistin Human genes 0.000 title abstract description 4
- 108010047909 Resistin Proteins 0.000 title abstract description 4
- 239000004816 latex Substances 0.000 claims abstract description 46
- 229920000126 latex Polymers 0.000 claims abstract description 46
- 238000001514 detection method Methods 0.000 claims abstract description 43
- 210000002966 serum Anatomy 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 239000000090 biomarker Substances 0.000 claims abstract description 16
- 230000001154 acute effect Effects 0.000 claims abstract description 14
- 206010033645 Pancreatitis Diseases 0.000 claims abstract description 9
- 206010033647 Pancreatitis acute Diseases 0.000 claims abstract description 9
- 201000003229 acute pancreatitis Diseases 0.000 claims abstract description 9
- 238000003908 quality control method Methods 0.000 claims abstract description 6
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract description 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims abstract description 4
- 238000002525 ultrasonication Methods 0.000 claims description 28
- 230000001235 sensitizing effect Effects 0.000 claims description 20
- 208000007743 Acute Abdomen Diseases 0.000 claims description 18
- 238000005516 engineering process Methods 0.000 claims description 16
- 239000004793 Polystyrene Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 13
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000013016 damping Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 239000004005 microsphere Substances 0.000 claims description 10
- 238000004321 preservation Methods 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000011835 investigation Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 229920002223 polystyrene Polymers 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
- 206010003011 Appendicitis Diseases 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 239000008363 phosphate buffer Substances 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 206010034674 peritonitis Diseases 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 238000004375 physisorption Methods 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 238000007689 inspection Methods 0.000 abstract description 4
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 3
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 238000005406 washing Methods 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 108010048233 Procalcitonin Proteins 0.000 description 38
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 38
- -1 SSA Proteins 0.000 description 13
- 238000012360 testing method Methods 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000004879 turbidimetry Methods 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- 102000054727 Serum Amyloid A Human genes 0.000 description 3
- 208000012873 acute gastroenteritis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001523209 Antissa Species 0.000 description 2
- 101710190759 Serum amyloid A protein Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 201000010312 acute cholangitis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
样本量 | 试剂量(R1/R2) | 反应温度 | 反应时间(T1/T2) |
5μL | 200μL/50μL | 37℃ | 300秒/300秒 |
单位 | 反应方向 | 标准曲线模拟方程 |
mg/L | 向上 | 多点定标,非线性计算模式 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510176406.XA CN104820099B (zh) | 2015-04-14 | 2015-04-14 | 一种同时检测血浆中TPSⅡ、SSA、hs‑CRP、PCT和抵抗素含量的试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510176406.XA CN104820099B (zh) | 2015-04-14 | 2015-04-14 | 一种同时检测血浆中TPSⅡ、SSA、hs‑CRP、PCT和抵抗素含量的试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104820099A true CN104820099A (zh) | 2015-08-05 |
CN104820099B CN104820099B (zh) | 2017-03-08 |
Family
ID=53730451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510176406.XA Expired - Fee Related CN104820099B (zh) | 2015-04-14 | 2015-04-14 | 一种同时检测血浆中TPSⅡ、SSA、hs‑CRP、PCT和抵抗素含量的试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104820099B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105372434A (zh) * | 2015-08-13 | 2016-03-02 | 浙江卓运生物科技有限公司 | 人血清淀粉样蛋白a检测试剂盒 |
CN105928907A (zh) * | 2016-05-17 | 2016-09-07 | 深圳普门科技有限公司 | 一种基于散射比浊技术的红细胞渗透脆性测定方法 |
CN108722507A (zh) * | 2018-06-21 | 2018-11-02 | 微粒云科技(北京)有限公司 | 一种炎症四项标志物磁微粒微流控生物芯片、检测方法 |
CN109521200A (zh) * | 2018-12-29 | 2019-03-26 | 南京新耀医疗技术有限公司 | 一种同时检测血浆中多种成分含量的试剂盒、方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101881777A (zh) * | 2010-06-30 | 2010-11-10 | 深圳市国赛生物技术有限公司 | 超敏c反应蛋白检测方法及超敏c反应蛋白检测试剂盒 |
CN103018464A (zh) * | 2012-12-12 | 2013-04-03 | 元升生物科技(上海)有限公司 | 一种测定降钙素原的试剂及该试剂的制备方法 |
CN103308681A (zh) * | 2013-06-25 | 2013-09-18 | 武汉生之源生物科技有限公司 | 胰蛋白酶原-2检测试剂盒及制备方法 |
-
2015
- 2015-04-14 CN CN201510176406.XA patent/CN104820099B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101881777A (zh) * | 2010-06-30 | 2010-11-10 | 深圳市国赛生物技术有限公司 | 超敏c反应蛋白检测方法及超敏c反应蛋白检测试剂盒 |
CN103018464A (zh) * | 2012-12-12 | 2013-04-03 | 元升生物科技(上海)有限公司 | 一种测定降钙素原的试剂及该试剂的制备方法 |
CN103308681A (zh) * | 2013-06-25 | 2013-09-18 | 武汉生之源生物科技有限公司 | 胰蛋白酶原-2检测试剂盒及制备方法 |
Non-Patent Citations (12)
Title |
---|
RAFFAELE PEZZILLI ET AL: "SerumAmyloidA,Procalcitonin,and C-ReactiveProtein in Early Assessment of Severity of Acute Pancreatitis", 《DIGESTIVE DISEASES AND SCIENCES》 * |
余天会 等: "血清降钙素原在感染性疾病诊治中的临床应用", 《检验医学与临床》 * |
戴佩佩 等: "降钙素原与C反应蛋白联合检测在细菌感染中的应用", 《检验医学》 * |
王晓岩 等: "抵抗素和高敏C反应蛋白诊断急性阑尾炎的价值探讨", 《中国煤炭工业医学杂志》 * |
胡新德 等: "PCT、 hs-CRP和血小板在新生儿败血症诊断中的价值及与病情的关系", 《中国现代医生》 * |
谭坤 等: "抵抗素与消化***疾病关系的研究进展", 《中国现代医药杂志》 * |
费凤英 等: "血清淀粉样蛋白A与C反应蛋白联合检测的临床应用价值", 《检验医学》 * |
郑彬: "急性上消化道穿孔患者术前血清C 反应蛋白的测定及其临床意义", 《赣南医学院学报》 * |
郭浚 等: "PCT、hs-CRP及IL-6 的水平变化对急性胰腺炎的临床意义", 《胃肠病学和肝病学杂志》 * |
陈军 等: "急性胰腺炎患者血清抵抗素的变化及其意义", 《现代预防医学》 * |
黄爱芳: "超敏C反应蛋白、白细胞计数联合检测对诊断小儿急性阑尾炎的临床意义", 《检验医学与临床》 * |
黎朝良 等: "急性肠梗阻患者血清降钙素原检测的临床意义", 《中华临床医师杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105372434A (zh) * | 2015-08-13 | 2016-03-02 | 浙江卓运生物科技有限公司 | 人血清淀粉样蛋白a检测试剂盒 |
CN105928907A (zh) * | 2016-05-17 | 2016-09-07 | 深圳普门科技有限公司 | 一种基于散射比浊技术的红细胞渗透脆性测定方法 |
CN108722507A (zh) * | 2018-06-21 | 2018-11-02 | 微粒云科技(北京)有限公司 | 一种炎症四项标志物磁微粒微流控生物芯片、检测方法 |
CN109521200A (zh) * | 2018-12-29 | 2019-03-26 | 南京新耀医疗技术有限公司 | 一种同时检测血浆中多种成分含量的试剂盒、方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104820099B (zh) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101377492B (zh) | 胱抑素c测定试剂盒 | |
CN102253217B (zh) | 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN103403549B (zh) | 败血症的预后的预测方法 | |
CN106198961A (zh) | 一种定量检测血清淀粉样蛋白a的乳胶增强免疫比浊试剂盒及其制备方法 | |
CN107727869A (zh) | 一种测定血清中抗核抗体的试剂盒及其制备方法 | |
CN108613977B (zh) | 一种n末端脑钠肽前体检测试剂盒 | |
CN103852584A (zh) | 一种定量检测c肽的胶乳增强免疫比浊试剂盒 | |
CN104820099A (zh) | 一种同时检测血浆中TPSⅡ、SSA、hs-CRP、PCT和抵抗素含量的试剂盒及其应用 | |
CN104849473A (zh) | 一种尿微量白蛋白检测试剂盒及其制备 | |
Fortunato | A new sensitive automated assay for procalcitonin detection: LIAISON® BRAHMS PCT® II GEN | |
CN109521200A (zh) | 一种同时检测血浆中多种成分含量的试剂盒、方法及其应用 | |
CN104764886B (zh) | 糖尿病肾病早期检测试纸盒、生物标志物检测方法及应用 | |
CN112014577B (zh) | 一种提高gpc3检测灵敏度的试剂盒及其制备方法 | |
CN105548547A (zh) | 基于流式细胞仪的检测肺癌标志物的流式阵列免疫分析试剂盒 | |
CN107045062A (zh) | 检测人ngal的胶体金免疫层析试纸条、试剂盒及其制备方法 | |
CN204479594U (zh) | 基于生物标志物的糖尿病肾病早期检测试剂盒 | |
CN105403712A (zh) | 一种高性能的人尿液α1酸性糖蛋白检测试剂盒 | |
CN204479593U (zh) | 基于生物标志物的肾损伤检测试剂盒 | |
Karam et al. | Whole-blood validation of a new point-of-care equine serum amyloid A assay | |
CN108802400B (zh) | 一种检测复合物IgA1-α1MG的方法及无创检测肾组织损伤的试剂盒 | |
CN106366199A (zh) | 一种肌钙蛋白i单克隆抗体磁微粒及其制备方法和检测试剂盒 | |
CN107918020B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒 | |
CN103698284B (zh) | 一种测定Lambda游离轻链浓度的试剂盒及方法 | |
Tecles et al. | Validation of a commercially available human immunoturbidimetric assay for haptoglobin determination in canine serum samples | |
CN103728455A (zh) | 一种测定Kappa游离轻链浓度的试剂盒及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191230 Address after: 312000 211, floor 2, building 9, No. 159, Meilin Road, Qixian street, Keqiao District, Shaoxing City, Zhejiang Province Patentee after: Xinji (Shaoxing) Biotechnology Co.,Ltd. Address before: Lishui District of Nanjing City, Jiangsu province 210012 Yong Yang Town Natural Bridge Road No. 688 Branch Center Patentee before: NANJING GEYAO BIOTECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220323 Address after: 215002 station 420-75, 4th floor, Yuanhe building, No. 959, Jiayuan Road, Yuanhe street, Xiangcheng District, Suzhou City, Jiangsu Province (cluster registration) Patentee after: Suzhou puluoli Biotechnology Co.,Ltd. Address before: 312000 211, floor 2, building 9, No. 159 Meilin Road, Qixian street, Keqiao District, Shaoxing City, Zhejiang Province Patentee before: Xinji (Shaoxing) Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170308 |
|
CF01 | Termination of patent right due to non-payment of annual fee |